A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)

被引：0
|
作者：
Markman, B. [1 ]
Solomon, B. [2 ]
Nott, L. M. [3 ]
Roberts-Thomson, R. [4 ]
Hughes, B. [5 ]
Pavlakis, N. [6 ]
Davis, A. [7 ]
Brown, L. J. [8 ]
Parakh, S. [9 ]
Brungs, D. [10 ]
Bowyer, S. E. [11 ]
Nordman, I. [12 ]
Jennens, R. [13 ]
Warburton, L. [14 ]
Harris, S. J. [15 ]
Samuel, E. [16 ]
Ramanujam, S. [17 ]
Wang, A. [18 ]
Dumas, M. [19 ]
Gard, G. [19 ]
机构：
[1] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[3] Royal Hobart Hosp, Dept Med Oncol, Hobart, Tas, Australia
[4] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA, Australia
[5] Prince Charles Hosp, Canc Care Serv, Chermside, Qld, Australia
[6] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia
[7] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[8] Westmead Hosp, Med Oncol, Sydney, NSW, Australia
[9] Olivia Newton John Canc Res Inst, Med Oncol Dept, Heidelberg, Vic, Australia
[10] Wollongong Hosp, Dept Med Oncol, Illawarra Canc Ctr, Wollongong, NSW, Australia
[11] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia
[12] Calvary Mater Hosp Newcastle, Dept Med Oncol, Newcastle, NSW, Australia
[13] Peter MacCallum Canc Ctr, Med Oncol, East Melbourne, Vic, Australia
[14] Fiona Stanley Hosp, Dept Med Oncol, Perth, WA, Australia
[15] Bendigo Hlth, Ctr Canc, Bendigo, Vic, Australia
[16] Latrobe Reg Hosp, Med Oncol, Traralgon, Vic, Australia
[17] Griffith Base Hosp, Dept Med Oncol, Griffith, NSW, Australia
[18] Amgen Inc, CfOR, Sydney, NSW, Australia
[19] Walter & Eliza Hall Inst Med Res, Dept Oncol, Parkville, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
590P
引用
收藏
页码：S1700 / S1700
页数：1
相关论文
共 50 条
  • [21] Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
    Shahnam, Adel
    Davis, Alexander
    Brown, Lauren Julia
    Sullivan, Isaac
    Lin, Kevin
    Ng, Chien
    Yeo, Nicholas
    Kong, Benjamin Y.
    Khoo, Trisha
    Warburton, Lydia
    Da Silva, Ines Pires
    Mullally, William
    Xu, Wen
    O'Byrne, Ken
    Bray, Victoria
    Pal, Abhijit
    Mersaides, Antony
    Itchins, Malinda
    Arulananda, Surein
    Nagrial, Adnan
    Kao, Steven
    Alexander, Marliese
    Lee, Chee Khoon
    Solomon, Benjamin
    John, Thomas
    LUNG CANCER, 2025, 201
  • [22] Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Palma, Gabriela
    Khurshid, Faisal
    Lu, Kevin
    Woodward, Brian
    Husain, Hatim
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [23] Clinical outcome of KRAS-mutated advanced non-small cell lung cancer (NSCLC) patients (pts): A mono-institutional analysis.
    Chiari, R.
    De Angelis, V.
    Bennati, C.
    Molica, C.
    Metro, G.
    Duranti, S.
    Tofanetti, F. R.
    Ludovini, V.
    Minotti, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Gabriela Palma
    Faisal Khurshid
    Kevin Lu
    Brian Woodward
    Hatim Husain
    npj Precision Oncology, 5
  • [25] Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
    Illini, Oliver
    Fabikan, Hannah
    Hochmair, Maximilian Johannes
    Weinlinger, Christoph
    Krenbek, Dagmar
    Brcic, Luka
    Setinek, Ulrike
    Terbuch, Angelika
    Absenger, Gudrun
    Konjic, Selma
    Valipour, Arschang
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [26] Real-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with KRAS G12C- mutated non-small cell lung cancer (NSCLC)
    Negrao, Marcelo V.
    Wu, Wen-Hsing
    Lindsay, Colin R.
    Caparica, Rafael
    Pretre, Vincent
    Kang, Yehrim
    Caro, Nydia
    Farago, Anna
    Ye, Fen
    de Castro, Gilberto, Jr.
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer
    Jing, Yawan
    Cheng, Ruixin
    Zeng, Hao
    Huang, Qin
    He, Dongyu
    Sun, Jiayi
    Tian, Panwen
    Li, Yalun
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 4507 - 4517
  • [28] Real world outcomes in KRAS G12C mutated metastatic colorectal cancer: An Australian retrospective analysis
    John, Alexius
    Cui, Wanyuan
    Muhandiramge, Jaidyn
    Johnson, Jeslin
    Lee, Margaret
    Dunn, Catherine
    Shapiro, Jeremy
    Loft, Matthew
    McKendrick, Joseph
    To, Yat Hang
    Wong, Hui Li
    Gibbs, Peter
    Tie, Jeanne
    Wong, Rachel
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 39 - 40
  • [29] 31507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
    Gadgeel, Shirish M.
    Miao, Jieling
    Riess, Jonathan W.
    Mack, Philip C.
    Gerstner, Gregory James
    Burns, Timothy F.
    Taj, Asma
    Akerley, Wallace L.
    Dragnev, Konstantin H.
    Moon, James
    Gandara, David R.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] KRAS p.G12 mutated advanced non-small cell lung cancer: Characteristics and outcomes from a Danish nationwide retrospective observational study
    Frost, Matilde
    Gotfredsen, Ditte Resendal
    Jensen, Kristoffer Jarlov
    Sorensen, Anne Mette Skov
    Louie, Karly
    Sroczynski, Nicholas
    Jakobsen, Erik
    Andersen, Jon
    Jimenez-Solem, Espen
    Petersen, Tonny
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 288 - 289
12345